Episode 165 - December 5, 2025

What It Covers

Biotech analysts examine 2026 sector outlook following strong 2025 rally, discussing FDA leadership changes under Rick Pazdur's resignation, regulatory uncertainty for rare disease therapies like UniQure's Huntington's treatment, IPO market predictions ranging from 15 to 50 companies, vaccine policy controversies, and competitive dynamics affecting data disclosure practices in oncology development.

Key Questions Answered

• •2026 Sector Outlook: Biotech enters third inning of rally after strong 2025 recovery, with XBI still below all-time highs despite recent gains. Key positive factors include successful drug launches from mid-sized companies like Insmed and Madrigal proving commercial viability, minimal drug pricing threats, and expected M&A activity. Primary remaining risk centers on FDA unpredictability, particularly for rare disease approvals with unvalidated endpoints.
• •IPO Market Predictions: Analysts forecast 15 to 50 biotech IPOs in 2026, significantly lower than the 100-plus peak during 2020-2022. Current pipeline features mid-to-late stage companies with derisked assets, contrasting sharply with previous cycle when companies filed S-1s with IND acceptance as primary catalyst. Public investors now participating in private rounds enables better incubation, creating institutionally relevant companies rather than illiquid venture investments.
• •FDA Leadership Vacuum: Rick Pazdur's resignation after three weeks as CDER director removes last senior FDA official with decades of institutional memory. CBER CSO Vinay Prasad actively inserting himself into approval decisions despite claims otherwise, creating unpredictability. Companies seeking CBER approvals should attempt direct engagement with Prasad and request his signature on meeting minutes to ensure alignment, though accessibility remains questionable.
• •Rare Disease Regulatory Risk: UniQure's Huntington's gene therapy faces approval rejection despite May breakthrough designation and agreed statistical analysis plan, with November FDA reversal attributed to leadership changes. Single-arm pivotal trials with natural history controls face heightened scrutiny under new leadership. Companies with pre-specified endpoints showing unprecedented efficacy on validated measures remain lower risk than slowly progressive diseases with functional endpoints.
• •Vaccine Policy Controversy: HHS and FDA pushing back against childhood vaccination schedules, with ACIP negative vote on at-birth hepatitis B vaccination receiving criticism. COVID vaccines remain flashpoint because they touch every healthy person, carry risks like myocarditis, and face social media amplification of safety questions. Passive immunity approaches using monoclonal antibodies from companies like Sanofi and Convivid may offer alternative without vaccine baggage.
• •Competitive Data Disclosure: Janex Therapeutics stock dropped 50 percent after selective PSMA bispecific data presentation, citing competitive dynamics with Chinese biotech as justification for withholding details. Management argues full disclosure enables competitors to draft off hard-won platform learnings. Investors generally discount opacity negatively, with only management teams having earned substantial trust able to maintain credibility through limited transparency in highly competitive spaces.